Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
22. Oktober 2024 08:00 ET
|
Allarity Therapeutics, Inc.
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China,...
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
25. Juni 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
Global PARP Inhibitors Cancer Therapy Market Outlook 2022-2028: PARP Inhibitors have Proved to be a Commercial Success in the Modern Cancer Therapeutic Segment
08. Juni 2022 04:43 ET
|
Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...
Global PARP Inhibitor Market To Grow At A CAGR Of 27.4% Due To Expanding Role Of PARP Inhibitors In Cancer Treatment
22. Juli 2020 08:30 ET
|
Quince Market Insights
Pune, India, July 22, 2020 (GLOBE NEWSWIRE) -- Global PARP Inhibitor Market was valued at USD 924 million in 2018 and predicted to grow at an exponential CAGR of 27.4% during the forecast period....
Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program
13. Juli 2020 08:28 ET
|
Oncology Venture A/S
Hoersholm, Denmark (13 July 2020) – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) announced today that it has secured the remaining ownership in its priority PARP...
ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System
18. Dezember 2019 16:30 ET
|
ChemioCare
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the...
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
30. September 2019 06:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy
15. Mai 2019 17:01 ET
|
Cybrexa Therapeutics
Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP...
Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity
02. April 2019 08:00 ET
|
Cybrexa Therapeutics
Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors Poster presentation today during AACR Annual Meeting 2019 ...
TESARO Announces Data Presentations at ESMO 2018 Congress
20. Oktober 2018 01:30 ET
|
TESARO, Inc.
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen...